Text Size

Troponin Elevation in the Elderly Patient With Hip Fracture

This study is currently recruiting participants.
Verified June 2012 by Sheba Medical Center
Sponsor:
Information provided by (Responsible Party):
Dr. Marina Arad, Sheba Medical Center
ClinicalTrials.gov Identifier:
NCT00647309
First received: March 26, 2008
Last updated: June 11, 2012
Last verified: June 2012
History of Changes
  Purpose

Elevated troponin is powerful and independent adverse prognostic marker in patient with ACS. However, non specific (non cardiac) troponin elevation is a common finding among hospitalized patients and worse prognosis too.

The aim of this study is examine the prevalence of incidental cardiac troponin rise in a group of patient aged 65 and over admitted to geriatric department with hip fracture, and influence of troponin elevation on outcomes like ACS, death, motor and cognitive function.


Condition
Hip Fracture

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Correlation Between Troponin Level and Rehabilitation Outcome in Elderly Patient With Hip Fracture

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Sheba Medical Center:

Primary Outcome Measures:
  • all cause mortality, motor and cognitive function [ Time Frame: one year ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

whole blood


Estimated Enrollment: 100
Study Start Date: April 2008
Estimated Study Completion Date: June 2013
Estimated Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)

Detailed Description:

data collection will include epidemiological data (age, gender, living arrangement, basic functional status, fracture date, surgery date, surgery type, length of stay) as well as previous comorbidities. in addition, routine blood tests and baseline ECG will be recorded.

troponin levels will be studied within 24 hours from admission, and 24 hours following surgery. in case of elevated troponin levels, ECG will be repeated, and echocardiography together with a cardiologist evaluation will be carried out.

data regarding in-hospital complications, motor and cognitive function (by FIM scale) and lab will be recorded. after discharge. followup will be recorded every 3 months, up to 1 year period, recoding the above mentioned data.

  Eligibility

Ages Eligible for Study:   65 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

patients aged 65 years and over with hip fracture

Criteria

Inclusion Criteria:

  • Age 65 and over with hip fracture

Exclusion Criteria:

  • None
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00647309

Locations
Israel
Sheba Medical Center, Geriatric Rehabilitation dept Recruiting
Ramat Gan, Israel, 52621
Contact: Arad Marina, MD     973-3-5305108     aradm@post.tau.ac.il    
Principal Investigator: arad marina, MD            
Sub-Investigator: Adunsky Abraham, MD            
Sponsors and Collaborators
Sheba Medical Center
Investigators
Principal Investigator: Marina Arad, MD Sheba Medical Center
  More Information

No publications provided

Responsible Party: Dr. Marina Arad, md, Sheba Medical Center
ClinicalTrials.gov Identifier: NCT00647309     History of Changes
Other Study ID Numbers: SHEBA-08-5096-MA-CTIL
Study First Received: March 26, 2008
Last Updated: June 11, 2012
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Additional relevant MeSH terms:
Fractures, Bone
Hip Fractures
Wounds and Injuries
 Femoral Fractures
Hip Injuries
Leg Injuries

ClinicalTrials.gov processed this record on May 23, 2013